ALDX - Aldeyra The logo

ALDX

Aldeyra The

Rev โ€”top 1%10Y
Hold

Aldeyra Therapeutics develops therapies for immune-mediated diseases, focusing on reactive aldehyde species (RASP). Its main products include reproxalap for dry eye disease, ADX-2191 for primary vitreoretinal lymphoma, and ADX-629 for COVID-19 and asthma.

โš•๏ธ Healthcare NASDAQ Listed 2014 $ USD
$1,000 invested 10 years ago โ†’$264today

Score Overview

1 Year
Scoreโ€”
Net Growth19.14%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Scoreโ€”
Net Growth52.63%
Net Trend60%
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendNever
Revenue Consistencyโ€”
10 Years
Scoreโ€”
Net Growth-46.37%
Net Trend40%
Net Income Consistency
Rev Growthโ€”
Rev TrendNever
Revenue Consistency
All Time
Scoreโ€”
Net Growth-427.66%
Net Trend33%
Net Income Consistency
Rev Growthโ€”
Rev TrendNever
Revenue Consistency

See the full market ranking โ†’

Aldeyra The fundamental performance

Across Aldeyra The's full reported history, from 2014 to 2025, revenue held from $ 0.00 to $ 0.00 and net income went from -$ 5M to -$ 33M. Revenue increased in 0% of the years measured; net income in 33%.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 1.52โ€”
1 Year2025-08-12
$ 5.36-71.64%
5 Years2021-08-12
$ 9.60-84.17%
10 Years2016-08-12
$ 5.76-73.61%
All Time2014-05-02
$ 7.20-78.89%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 0.00-$ 27M$ 65M
2025$ 0.00-$ 33M$ 70M
2024$ 0.00-$ 55M$ 101M
2023$ 0.00-$ 37M$ 142M
2022$ 0.00-$ 62M$ 174M
2021$ 0.00-$ 57M$ 229M
2020$ 0.00-$ 37M$ 77M
2019$ 0.00-$ 60M$ 73M
2018$ 0.00-$ 38M$ 93M
2017$ 0.00-$ 22M$ 42M
2016$ 0.00-$ 18M$ 24M
2015$ 0.00-$ 12M$ 27M
IPO2014$ 0.00-$ 5M$ 8M

Explore beyond ALDX

You're looking at Aldeyra The. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies